Lower ICS dose effect on symptoms and rescue medication use of indacaterol/glycopyrronium/mometasone (IND/GLY/MF) medium-dose vs salmeterol/fluticasone (Sal/Flu) high-dose plus tiotropium (Tio): ARGON study
C. Gessner (Leipzig, Germany), O. Kornmann (Frankfurt, Germany), J. Maspero (Buenos Aires, Argentina), R. Zyl-Smit (Cape Town, South Africa), M. Krüll (Berlin, Germany), A. Sojo (Cáceres, Spain), A. Salina (Basel, Switzerland), P. Gupta (Hyderabad, India), L. Conde (Basel, Switzerland)
Source: Virtual Congress 2020 – Inhaled corticosteroids and bronchodilator studies in asthma
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. Gessner (Leipzig, Germany), O. Kornmann (Frankfurt, Germany), J. Maspero (Buenos Aires, Argentina), R. Zyl-Smit (Cape Town, South Africa), M. Krüll (Berlin, Germany), A. Sojo (Cáceres, Spain), A. Salina (Basel, Switzerland), P. Gupta (Hyderabad, India), L. Conde (Basel, Switzerland). Lower ICS dose effect on symptoms and rescue medication use of indacaterol/glycopyrronium/mometasone (IND/GLY/MF) medium-dose vs salmeterol/fluticasone (Sal/Flu) high-dose plus tiotropium (Tio): ARGON study. 2634
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Bronchodilator response of single dose of tiotropium (Tio) plus formoterol (Formo) versus four doses of ipratopium (Ipra) plus salbutamol (Salb) over 24 hours in subjects with moderate-to-severe stable COPD Source: Annual Congress 2008 - Diagnosing, monitoring and treating respiratory diseases in primary care Year: 2008
Improved control and compliance in children is achieved with salmeterol/fluticasone combination (SFC) compared with concurrent long-acting β2 agonists (LABA) + inhaled corticosteroids (ICS) Source: Eur Respir J 2003; 22: Suppl. 45, 312s Year: 2003
Variability in asthma and treatment efficacy as determined by weekly response rates with fluticasone propionate/salmeterol 100/50mcg (FSC) compared with montelukast 10mg (MON) Source: Eur Respir J 2003; 22: Suppl. 45, 259s Year: 2003
Sequential flexible therapy with formoterol (Foradil®) plus budesonide (Miflonide®) versus a fixed combination of salmeterol and fluticasone (Seretide®) in asthma self-management Source: Eur Respir J 2002; 20: Suppl. 38, 388s Year: 2002
Eight weeks of treatment with tiotropium plus fluticasone (t+f) produces an equally effective therapeutic response as salmeterol plus fluticasone (s+f) in subjects with moderate-to-severe asthma Source: Annual Congress 2009 - Towards improving asthma control Year: 2009
Budesonide/formoterol for maintenance and relief vs. higher dose ICS/LABA therapy: outcomes in patients symptomatic on high-dose inhaled corticosteroids (HDICS) Source: Annual Congress 2007 - Recent advances in our understanding of the mechanisms of asthma treatment Year: 2007
Safety and tolerability of the novel inhaled corticosteroid (ICS) fluticasone furoate (FF) in combination with the long-acting beta2 agonist (LABA) vilanterol (VI) administered once daily (OD) in patients with asthma Source: Annual Congress 2012 - Asthma treatment: efficacy and safety Year: 2012
Inhaled corticosteroid (ICS) and long-acting beta2-agonist (LABA) combination vs. high doses of ICS: efficacy and safety in patients (pts) with uncontrolled occupational asthma Source: International Congress 2017 – Techniques to treat asthma Year: 2017
Once-daily indacaterol/glycopyrronium (IND/GLY) reduces use of rescue medication versus twice-daily salmeterol/fluticasone (SFC) in patients with moderate-to-very severe COPD: results from the FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016
LATE-BREAKING ABSTRACT: TRINITY: A phase III study to compare the efficacy and safety of an extrafine triple combination of beclometasone dipropionate (BDP), formoterol fumarate (FF), and glycopyrronium bromide (GB) pMDI (CHF5993) with tiotropium (Tio) and a free triple combination of BDP/FF (Foster®) + Tio in COPD patients Source: International Congress 2016 – Late-breaking topics in airways disease Year: 2016
Efficacy and safety of inhaled corticosteroid‘s (ICS) and long-acting beta-agonist‘s (LABA) combination in asthma (A) patients Source: Eur Respir J 2004; 24: Suppl. 48, 125s Year: 2004
Superiority of the ‘triple‘ therapy of salmeterol/fluticasone propionate (SFC) and tiotropium (TIO) vs. individual components in COPD Source: Annual Congress 2007 - New drugs for COPD Year: 2007
Comparison of the short-term effect of tiotropium (TIO) vs a combination therapy with single inhaler budesonide/formoterol (symbicort) on the degree of pulmonary hyperinflation Source: Eur Respir J 2004; 24: Suppl. 48, 21s Year: 2004
Relation between the acute response to salbutamol and long-term FEV1 responses to tiotropium (TIO), formoterol (FORM) and its combination (T+F) in COPD patients Source: Eur Respir J 2003; 22: Suppl. 45, 4s Year: 2003
Salmeterol/fluticasone combination (SFC) is associated with improved asthma control compared with concurrent long-acting β2 agonists (LABA) and inhaled corticosteroids (ICS) or ICS alone Source: Eur Respir J 2003; 22: Suppl. 45, 235s Year: 2003
LATE-BREAKING ABSTRACT: ENERGITO: Efficacy and safety of once-daily combined tiotropium + olodaterol versus twice-daily combined fluticasone propionate + salmeterol Source: International Congress 2015 – Emerging strategies for airway disease treatments Year: 2015
Lower systemic exposure to corticosteroid for fluticasone propionate/salmeterol (500/50mcg bd) compared to budesonide/formoterol (400/12mcg bd) administered via combination dry powder inhalers in subjects with COPD Source: Eur Respir J 2006; 28: Suppl. 50, 205s Year: 2006
INTREPID study: Once-daily single-inhaler fluticasone furoate/umeclidinium/vilanterol vs multiple-inhaler triple therapy; sub-analysis by prior medication strata Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more Year: 2020
Control of airway inflammation is maintained in asthma patients following a 60% reduction in ICS dose with fluticasone propionate/salmeterol (FSC) compared with higher dose fluticasone propionate (FP) alone Source: Eur Respir J 2004; 24: Suppl. 48, 308s Year: 2004
Fluticasone furoate (FF), an inhaled corticosteroid (ICS), demonstrates efficacy in asthma patients symptomatic on moderate doses of ICS therapy Source: Annual Congress 2010 - New treatments for asthma and COPD Year: 2010